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Abstract: Onychomycosis is mainly caused by two dermatophyte species, Trichophyton rubrum and
Trichophyton interdigitale. A study of nail invasion mechanisms revealed that the secreted subtilisin
Sub6, which has never been detected under in vitro growth conditions, was the main protease secreted
by T. rubrum and T. interdigitale during infection. In contrast, most of the proteases secreted during
the digestion of keratin in vitro were not detected in infected nails. The hypothesis that proteases
isolated from dermatophytes grown in a keratin medium are virulence factors is no longer supported.
Non-dermatophyte fungi can also be infectious agents in nails. It is necessary to identify the infectious
fungus in onychomycosis to prescribe adequate treatment, as moulds such as Fusarium spp. and
Aspergillus spp. are insensitive to standard treatments with terbinafine or itraconazole, which are
usually applied for dermatophytes. In these refractory cases, topical amphotericin B treatment has
shown to be effective. Terbinafine treatment failure against dermatophytes is also possible, and is
usually due to resistance caused by a missense mutation in the squalene epoxidase enzyme targeted
by the drug. Trichophyton resistance to terbinafine treatment is an emerging problem, and a switch to
azole-based treatment may be necessary to cure such cases of onychomycosis.
Keywords: onychomycosis; Trichophyton; Fusarium; Acremonium; Aspergillus; terbinafine; itraconazole;
amphotericin B; antifungal drug resistance
1. Introduction
Two species of dermatophyte, Trichophyton rubrum and Trichophyton interdigitale, are the cause of
most onychomycosis, often following fungal infection of the interdigital or plantar spaces [1]. However,
the infectious agents of nail infections are not only dermatophytes but also moulds and yeasts of
the genus Candida. Dermatophyte onychomycosis is also called tinea unguium. The diagnosis of
onychomycosis is usually primarily based on the detection of a fungus in nail samples by direct
mycological examination, then on the isolation and identification of the infectious fungus in culture [1].
The purpose of this article is to briefly review recent findings on fungal nail infection and to present
new perspectives for improving their treatment. Tools for the diagnosis of onychomycosis and rapid
identification of the pathogen, which remain a challenge for the clinician, are summarized in Table 1.
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Table 1. Tools for the diagnosis of onychomycosis and rapid identification of the pathogen.
Methods Target Usage § Time Specificity # References
Direct Mycological
Examination
Hyphae and
spores in nails PP, RL 2–5 min
Fungi (Trichophyton,
NDMs, Yeasts) [2–5]
Cultures Growing fungi RL 7–14 days
Tru, Tint
NDMs if repeated isolations
Yeasts if repeated isolations
[6]
PCR with Specific
Primers
Nail fungal
DNA RL 5 h Tru [7–9]
PCR with Pan-Fungal
Primers /Sequencing
Nail fungal
DNA RL 24 h
Trichophyton
NDMs
Yeasts
[10,11]
Mass Spectrometry
(MRM) Sub6 RD Tru, Tint [12]
Western Blotting Sub6 RD 24 h Trichophyton [13]
ELISA Sub6 ND 24 h Trichophyton [13]
Strip Tests Polysaccharides PP 15 min Trichophyton [14–18]
§ PP: usage in private practice; RL: usage in routine laboratory; RD: for research and development. # NDM:
non-dermatophyte filamentous mould; Tru: T. rubrum; Tint: T. interdigitale.
2. Direct Mycological Examination of Nail Samples
Various skin diseases look like but are not mycoses. Before any drugs are prescribed, direct mycological
examination of skin, nail, or hair samples is an essential step for confirming the clinical diagnosis
of fungal infection in dermatology. Many laboratories still use 20%–30% KOH solution to dissociate
dermatological samples [1]. Another effective solution for the dissociation of keratinized samples is a
1:1 mixture of water and ethanol containing 10% Na2S [2].
It is difficult to detect fungal elements using light microscopy without contrast. Direct microscopical
examination using fluorochromes, which specifically bind to vegetal and fungal cell wall polysaccharides,
is by far the most sensitive contrasting technique for detecting hyphae and spores in dermatological
samples [2–5]. When the preparation is illuminated by light with a wavelength between 360 and 440 nm,
the hyphae and spores become fluorescent and are immediately detected (Figure 1). Fluorescence
microscopy allows for better observation of fungal morphology. A recent improvement has been
the use of fluorescence microscopy with an LED light source, which intensifies the fluorescence.
In addition, LED lamps have a long service life and can be switched on without having to wait for the
lamp to cool down.
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3. Fungal Cultures from Nail Samples
The fungus is isolated after nail fragments are deposited on a nutrient agar medium. A commonly
used medium is Sabouraud supplemented with chloramphenicol to inhibit bacterial growth [1]. It is
also imperative to selectively promote the growth of dermatophytes while inhibiting the growth of
associated moulds, which generally grow relatively faster. Therefore, two cultures are generally carried
out in parallel, one with and the other without actidione in the medium [1]. This compound inhibits the
growth of most moulds, but not dermatophytes which are not sensitive to it. Yeasts develop in 24–48 h,
whereas non-dermatophyte filamentous moulds (NDMs) such as Aspergillus spp., Penicillium spp., and
Fusarium spp., which can be infectious or transient contaminants and the most frequent species of
contaminating saprophytes (Alternaria spp. and Curvularia spp.), develop in 3 to 5 days. Between 7
and 14 days are necessary for the growth and identification of dermatophytes.
4. Identification of Fungi In Situ in Nail Samples
Two problems arise when identifying fungi in dermatological samples when growing cultures.
(i) Often, the seeded tubes (or Petri dishes) remain sterile. It has been shown that no fungi grow in
about 35% of cases following a positive direct mycological examination [19]. (ii) Many NDMs are
isolated. It is frequently difficult to determine whether a mould is in fact the infectious agent causing
onychomycosis or a contamination. Using cultures, only repeated isolations of the same NDM indicate
its involvement in nail infection with some certainty [6,20].
Conventional PCR and real-time PCR techniques are now reliable and suitable for performing the
in situ identification of dermatophytes, yeasts, and NDMs in onychomycosis, provided that enough
nail material is collected by the clinician [21]. Several methods aim to detect one particular species with
specific primers [7–9]. Others aim to detect dermatophytes as well as NDMs and yeasts as infectious
agents in nail samples using pan-fungal primers [10,11]. The results of fungal identification obtained
by PCR in onychomycosis are representative of the infection at the time when the nail sample was
collected. PCR has significantly improved the diagnosis and treatment of onychomycosis. (i) NDMs
such as Fusarium spp., Acremonium spp., or Scopulariopsis spp. and yeasts have been identified as
infectious agents of onychomycosis and not as transient contaminants with certainty [10,11]. (ii) An
infectious agent can be identified in at least 70% of cases where a direct mycological examination
of the nails shows fungal elements, while negative results are obtained by fungal culture [10,11].
Obtaining results within 48 hours, whereas those from fungal cultures can take at least one week,
is another advantage. PCR identification of fungi in situ has shown a high prevalence of moulds in
onychomycosis. The prevalence of NDMs in onychomycosis has been estimated at approximately 20%
of cases, not including mixed infections [10,11]. The statistics provided on this subject from culture
results vary widely in the literature from 3% to 80% [22,23].
Immunological methods are another trend in the detection of onychomycosis. An anti-dermatophyte
monoclonal antibody that reacts with the cell wall polysaccharide antigen of dermatophytes was
recently produced [14]. The nature of the recognized antigen was not identified, but the epitope of this
antibody may be a carbohydrate moiety similar to the galactomannan or galactofuran of Aspergillus
detected by monoclonal antibodies in cases of invasive aspergillosis in immunocompromised patients.
Using this anti-dermatophyte monoclonal antibody and immunochromatography, test strips were
developed and validated [15–18]. Test strips are now available as new devices to detect Trichophyton in
infected nails (dermatophyte test Strip, JNC Corporation, Tokyo, Japan; FungiCheck, HFL Laboratories,
The Netherlands). Available test strips are dedicated to dermatophyte detection in dermatological
samples. However, the monoclonal antibody also reacts with Aspergillus flavus and Fusarium
solani [18]. While the latter are nail infectious agents, there are no data on their possible detection in
dystrophic nails.
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5. Mechanisms of Nail Invasion
The fungus can enter the nail through the distal subungual area and the lateral nail groove, through
the dorsal surface of the nail plate producing superficial onychomycosis, or through the under-surface
of the proximal fold of the nail [1]. Infection may also be secondary to paronychia. Dermatophyte
infections are often the result of an intertrigo, while repetitive strain injuries to the nail, especially
hallux, may play a major role in mould invasion.
Research on mechanisms of nail invasion, as well as that of other keratinized tissues, primarily
focuses on secreted proteases. All dermatophytes grow well in a medium containing hard keratin as
the sole source of carbon and nitrogen, and most secreted proteins in culture supernatant are proteases.
At alkaline pH, two subtilisins (Sub3 and Sub4) and metalloproteases of the fungalysin family (M36
family in the MEROPS database) are the major endoproteases secreted by dermatophytes, together with
exopeptidases. The latter comprises two leucine aminopeptidases of the M28 family (Lap1 and Lap2)
and two dipeptidyl-peptidases of the S9 family (DppIV and DppV) [24]. At acidic pH, dermatophytes
were found to secrete an aspartic protease of the pepsin family (Pep1) as an endoprotease and
tripeptidyl peptidases of the sedolisin family, X-prolyl peptidases and carboxypeptidases of the S10
family as exoproteases [25]. Proteases secreted in vitro were considered as virulence factors. However,
proteomic analysis of proteins extracted from infected nail beds of patients with onychomycosis
showed that particular subtilisin (Sub6), not detected in vitro, was the major secreted protease during
infection [12,13]. Additional secreted proteins were identified, among which was the closely related
Sub7 and the dipeptidyl peptidase DppV. Surprisingly, most proteases secreted in vitro during keratin
digestion were not detected during infection establishment [12,13]. These results were in accordance
with a transcriptomic study performed with RNA from guinea pigs infected by the dermatophyte
species Trichophyton benhamiae, which naturally infects guinea pigs [26]. RNA sequencing analysis
revealed that SUB6 was the major gene expressed by the fungus during infection. In contrast, the
genes encoding most of the major proteases secreted by the fungus in vitro were not found to be
expressed in vivo, which confirmed the results of proteomic analyses with clinical samples [12,13].
Therefore, the previous hypothesis that proteases isolated from dermatophytes grown in vitro in a
keratin medium are virulence factors and play a major role during nail and skin infection should be
abandoned. In summary, T. rubrum does not grow in the nails like a saprophyte, destroying dead
material, but grows parasitically like T. benhamiae in skin infection, attesting to the control of its
transcriptome by keratinocytes.
Sub6 and DppV were first identified and characterised as major allergens of T. rubrum, causing
immediate hypersensitivity and delayed-type hypersensitivity skin reactions [27]. Sub6 and DppV
antigens have been called Tri r 2 and Tri r 4, respectively. Trichophyton rubrum infections cause
severe asthma as a secondary immune reaction [28,29]. There is a strong association between
protein sensitisation of the fungus and the severity of asthma. Trichophyton asthma can be controlled
by systemic antifungal therapy [30,31]. Trichophyton asthma is not very common but is possibly
underestimated due to the lack of fungal extracts for intradermal skin tests to demonstrate sensitisation.
Sub6 was revealed to be a very specific biomarker of T. rubrum and T. interdigitale [12], and
monoclonal antibodies targeting T. rubrum and T. interdigitale Sub6 were developed for the detection
of dermatophytes in infected nails [13]. They allowed the detection of a 40-kDa band corresponding
to the full-length subtilisin and a 20 kDa band corresponding to a major degradation product of the
enzyme. These antibodies were used to identify dermatophyte onychomycosis by Western blotting
and ELISA with protein extracts from infected nails. As a perspective, Sub6 monoclonal antibodies
could be used to develop a new strip test for the rapid diagnosis of tinea unguium.
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6. Resistance of Onychomycoses to Standard Treatment
6.1. Antifungal Susceptibility Testing
The insensitivity of onychomycosis to standard antifungal therapy often leads to the request of
available antifungal resistance tests. While antifungal susceptibility testing is repeatedly requested
for Candida albicans and Aspergillus fumigatus, the absence or low sporulation of T. rubrum has always
been a major complication and a limiting factor to perform this analysis in routine. Guidelines
and the literature both list different media (e.g., SDA diluted 1/10, potato dextrose agar (PDA) and
oatmeal agar (OTA)) on which T. rubrum is supposed to sporulate easily [32,33]. However, variability
between strains remains present in these media with respect to quantitative sporulation. On the
other hand, Chin and Knight reported in 1957 that sporulation of T. rubrum under increased CO2
tension [34], and a combination of high CO2 tensions and incubation on PDA growth medium proved
to be optimal to obtain spores of this dermatophyte [35]. The availability of large quantities of
spores subsequently used as colony forming units allows the preparation of standardised inocula to
perform microdilution, checkerboard, disc diffusion, and Etest assays in the same way as for bacteria,
yeasts, and Aspergillus spp. CSLI guidelines specify the use of RPMI 1640 medium for antifungal
susceptibility tests [33]. However, SDA medium was found to be more advisable than RPMI medium
when working with T. rubrum because this species grows poorly on this medium in contrast to yeasts
and Aspergillus spp. [35].
6.2. Resistance of Dermatophytes to Standard Treatments
Terbinafine and azole are used extensively in therapy for dermatophyte infections. Terbinafine
inhibits the squalene epoxidase (SQLE) involved in an early step of ergosterol biosynthesis [36],
a compound essential for the structure and function of the plasma membrane in fungi. The resulting
intracellular accumulation of squalene is toxic to fungal cells [37]. Azoles such as itraconazole and
voriconazole act downstream of the squalene epoxidase reaction in membrane ergosterol synthesis.
These cytostatic antifungal drugs inhibit the lanosterol 14-α-demethylase encoded by ERG11 in
C. albicans and CYP51 in filamentous fungi [38]. Lanosterol 14-α-demethylase inhibition leads to
the accumulation of sterol precursors. A defect in the synthesis of ergosterol results in the alteration of
plasma membrane structure and function.
Increased exposure to antifungal drugs favours the generation of resistant microbes, and following
this trend, dermatophytes resistant to terbinafine have recently emerged in several countries [39–42].
The prevalence of terbinafine-resistant Trichophyton rubrum nail isolates was found to be 1.0% in
Switzerland (26 cases among 2056 tested isolates) [39] and unpublished work: Monod, M. et al.
manuscript in preparation. The DNA sequence of the gene encoding SQLE in 17 T. rubrum clinical
isolates from tinea pedis and tinea unguium in Switzerland with reduced terbinafine susceptibility
revealed single-point mutations, leading to amino acid substitutions at one of the four amino acid
positions (Leu393, Phe397, Phe415 and His440) within the SQLE protein. Four of the 17 T. rubrum
isolates harboured the same Leu393Phe mutation previously identified in one clinical isolate by
Osborne et al. [43], and four other isolates harboured the same Phe397Leu mutation previously
identified in another clinical isolate by the same author [44]. These two mutations were detected in
terbinafine-resistant T. mentagrophytes causing tinea cruris in India, attesting to the prevalence of these
mutations in resistant dermatophyte clinical isolates [42]. Introduction of the detected point mutations
into terbinafine-sensitive T. mentagrophytes generated terbinafine-resistant phenotypes for which the
terbinafine MIC was comparable to that of corresponding clinical strains [39]. These results showed
that terbinafine resistance in Trichophyton clinical isolates had to be imputed to the detected amino
acid substitution in the SQLE protein. Trichophyton resistance to terbinafine treatment is an emerging
problem, and a switch to azole-based treatment may be necessary to cure such cases of onychomycosis.
In addition to missense mutations in the genes encoding the drug target, antifungal resistance
can also be mediated by overexpression of genes encoding multidrug transporters (MDR) in many
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fungi such as C. albicans and A. fumigatus [45,46]. Two dermatophyte ATP-binding-cassette (ABC)
transporter genes, called MDR1 and MDR2 (for multidrug resistance 1 and 2, respectively), have
been reported [47,48]. Although increased expression levels of MDR1 and MDR2 were observed in
response to stress caused by sub-inhibitory levels of various antifungal compounds, nothing is known
about the ability of both transporters to function as efflux pumps for azoles. We recently isolated
a strain (TIMM20092) from a patient insensitive to standard treatment with terbinafine or azoles.
A mutation of the squalene epoxidase, which is targeted by terbinafine, has been detected in this strain,
while resistance to azoles could be attributed to drug efflux pumps (Monod, M. et al. manuscript in
preparation). Although still exceptional in onychomycosis in Europe, resistance to azoles seems to be
common in India in Trichophyton mentagrophytes isolated from skin dermatophytosis [42,49].
6.3. Insensitivity of NDM Onychomycosis to Standard Treatments Used for T. unguium
Fungal cultures performed in many cases of onychomycosis, insensitive to conventional
oral treatments with terbinafine and/or itraconazole, do not reveal the presence of T. rubrum or
T. interdigitale, and treatment failure cannot be attributed to acquired resistance. Pan-fungal PCR
using DNA extracted from nail samples showed that an NDM (Fusarium sp., Acremonium sp. or
Aspergillus sp.) was the infectious fungus in such cases [50,51]. Numerous reports based on the
identification of the fungus in culture have shown that onychomycoses due to Fusarium sp. [52–55] are
difficult to treat. Fusarium sp. generally affects the nail of the big toe (hallux), especially in patients
who have suffered trauma or repetitive injuries. A mould must be suspected of being the infectious
agent of onychomycosis upon failure of several treatments, with a positive direct examination without
dermatophytes in culture, and a hallux infection without any other sign of inter-toe, plantar or
anamnestic mycotic fungus of the foot.
For Fusarium sp., Acremonium sp. and Aspergillus sp. onychomycosis, a topical treatment is prescribed
consisting of daily application of an amphotericin B solution (2.0 mg/mL in a 1:1 mixture of DMSO
and isopropyl alcohol) [51]. Amphotericin B is a broad-spectrum antifungal agent of the polyene
class and is fungicidal. This antifungal compound forms channels in the cell membrane of the fungus
that allow ions and organic compounds of the cytoplasm to escape, thereby destroying membrane
function [56]. In a pilot trial, treatment was effective in all patients (n = 8) [51]. Nails showed a
healthy appearance after 6–12 months of solution application, and direct mycological examination was
negative. The application of amphotericin B as a topical solution is a safe and relatively inexpensive
treatment of choice for onychomycosis caused by moulds (Figure 2) [51,57].
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7. Conclusions
While direct examination remains essential in medical mycology, a positive direct examination
does not automatically mean that the infecting fungus is a dermatophyte. The identification of the infectious
agent in onychomycosis, at least at the genus level, is very important for appropriate treatment
prescription, before any investigation regarding possible acquired resistance by a dermatophyte.
Cases of dermatophyte resistance to antifungal agents in nails are still rare (about 1%), and most
cases of onychomycosis insensitive to standard treatments with terbinafine and azoles are due to
mould infection.
In many laboratories, direct mycological examination and culture are performed routinely for
each suspected case of onychomycosis. The development of PCR methods is underway to automate the
analysis of onychomycosis samples. However, automation could be problematic because the material
collected varies from a few nail scrapings to the entire nail. For example, 830 samples received out of
2267 could not be retained due to a lack of collected material in a study where real-time PCR results
were compared to cultures [58]. The high rate of negative PCR results was on the order of 50% but the
samples were not selected by direct mycological examination. We observed in our laboratory that the
number of negative PCR results was greatly reduced by analysing only samples that are positive by
direct mycological examination. Direct mycological examination seems difficult to eliminate in the
laboratory because fungal elements can be detected in very little material.
With monoclonal antibodies, the dermatophyte strip tests for rapid detection of Trichophyton by
immunochromatography could be appropriate in private practice. The tests developed in Japan have
both high sensitivity and negative predictive value and are suitable for ruling out onychomycosis in
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doubtful cases [14–18]. Research on infected nails is technically demanding, but new knowledge of
onychomycosis has proven to be useful in improving diagnosis and optimal therapeutic prescription.
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